SCHEMBL627008

SCHEMBL627008

Fc1cc2nc(-n3cccn3)nc(N3CCOCC3)c2cc1N1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.50
LMNA P02545 1/20 0.50
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
ADORA2A P29274 3/20 0.47
EGLN1 Q9GZT9 7/20 0.45
PRKDC P78527 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MTOR P42345 2/20 0.39
PIK3CA P42336 1/20 0.39
JAK3 P52333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623390 0.94 ADORA2A (0.52) HTTLMNAALDH1A1KDM4EADORA2A
SCHEMBL627423 0.88 HTT (0.50) HTTLMNAALDH1A1KDM4EADORA2A
SCHEMBL14992352 0.82 EGLN1 (0.52) HTTLMNAALDH1A1KDM4EADORA2A
SCHEMBL16626234 0.81 KDM4E (0.55) HTTLMNAALDH1A1KDM4EADORA2A
SCHEMBL14992034 0.81 EGLN1 (0.69) HTTLMNAALDH1A1KDM4EADORA2A
SCHEMBL27919330 0.81 ADORA2A (0.52) HTTLMNAALDH1A1ADORA2AEGLN1
SCHEMBL623201 0.80 EGLN1 (0.70) EGLN1
SCHEMBL16626202 0.79 EGLN1 (0.52) HTTLMNAALDH1A1KDM4EEGLN1
SCHEMBL14992529 0.79 EGLN1 (0.49) HTTLMNAALDH1A1KDM4EEGLN1
SCHEMBL627779 0.78 EGLN1 (0.49) HTTLMNAADORA2AEGLN1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-04-02 US disclosed
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-31 US disclosed
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 US disclosed
US-9573940-B2 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-16 US disclosed
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARAMCEUTICA NV (BE) 2014-10-16 US disclosed
US-8796263-B2 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-08-05 US disclosed
EP-2603502-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-06-19 EP disclosed
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2013-06-06 US disclosed
WO-2012021830-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 HTT 3365/4885LMNA 2683/4885ALDH1A1 171/4885
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 HTT 3365/4885LMNA 2683/4885ALDH1A1 171/4885
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 HTT 3861/4885LMNA 2625/4885ALDH1A1 84/4885
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 HTT 3358/4885LMNA 2667/4885ALDH1A1 132/4885
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 HTT 3365/4885LMNA 2683/4885ALDH1A1 171/4885
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 HTT 3861/4885LMNA 2625/4885ALDH1A1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.